Network meta- analysis revealed that in adolescents , intervention with 2000 mg/day metformin ranked better than other interventions ; however , 1000 mg/day metformin for 3 months may be most suitable for adolescents .
For adults , metformin at doses of 3000 and 1000 mg/day ranked the highest , other than minimeal and lifestyle interventions ; moreover , intervention with 3000 mg/day for 6 months and 1000 mg/day for 0.5 months may be suitable for adults .
Conclusion When considering the efficacy of interventions for losing weight , metformin offers clear advantages for overweight and obese population
Purpose Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta- analysis and to identify the most suitable dosage and intervention period for using metformin  in adolescents and adults .
Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study
Objective : To study the long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance . Patients : 181 African American subjects with insulin resistance and normal glucose tolerance test were r and omised to receive glipizide 5 mg/day ( n = 25 ) , metformin 500 mg/day ( n = 59 ) , or placebo ( n = 97 ) for 24 months . Insulin sensitivity , glucose tolerance , lipid profile , left ventricular mass ( echocardiography ) , aortic distensibility ( echocardiography , blood pressure ) , aortic pulse wave velocity ( PWV , carotid to femoral artery , Doppler ) were measured at baseline and at 12 and 24 months after r and omisation . Results : A significant increase in PWV was observed in both glipizide ( mean ( SEM ) change at 24 months 2.8 ( 2.7 ) m/s , p = 0.012 ) and metformin ( 2.2 ( 0.7 ) m/s , p = 0.01 ) groups during the follow up period . In contrast , PWV remained unchanged in the placebo group . The increase in PWV in the treatment groups was significant compared with placebo ( analysis of variance p < 0.05 ) . Other cardiovascular or metabolic variables did not change significantly compared with placebo during follow up . Conclusions : The observed increase in PWV is consistent with a decrease in the elastic properties of the aorta . The use of oral antidiabetic agents for the prevention of cardiovascular complications in non-diabetic African Americans with insulin resistance needs to be critically evaluated
Network meta- analysis revealed that in adolescents , intervention with 2000 mg/day metformin ranked better than other interventions ; however , 1000 mg/day metformin for 3 months may be most suitable for adolescents .
For adults , metformin at doses of 3000 and 1000 mg/day ranked the highest , other than minimeal and lifestyle interventions ; moreover , intervention with 3000 mg/day for 6 months and 1000 mg/day for 0.5 months may be suitable for adults .
Conclusion When considering the efficacy of interventions for losing weight , metformin offers clear advantages for overweight and obese population
Purpose Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta- analysis and to identify the most suitable dosage and intervention period for using metformin  in adolescents and adults .